Enanta Q2 FY2026 net loss narrows to $13.1M; Phase 1 trial started for EDP-978

ENANTA PHARMACEUTICALS INC

Revenue $17.2M from AbbVie royalties (up from $14.9M YoY); net loss $13.1M ($0.45/share) vs $22.6M loss YoY.
Cash $227M; runway into fiscal 2029; R&D spend $19.4M (down from $28.1M due to lower RSV trial costs).
Phase 1 dosing initiated for oral KIT inhibitor EDP-978; topline data expected Q4 2026.
Zelicapavir pivotal study enabling with FDA; update planned in Q2 2026; exploring BD opportunities.
Litigation: Federal Circuit oral arguments vs Pfizer; decision by Sept 2026; UPC hearing Sept 29.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

ENANTA PHARMACEUTICALS INC reported fiscal second quarter ended March 31, 2026 results: revenue $17.2 million, net income Net loss ... $13.1 million, EPS loss of $0.45 per diluted common share.

Period: fiscal second quarter ended March 31, 2026
Revenue: $17.2 million
Net income: Net loss ... $13.1 million
EPS: loss of $0.45 per diluted common share
Result: reported results

Exact text from the filing

multiple value-driving milestones over the coming year.” Fiscal Second Quarter Ended March 31, 2026 Financial Results Total revenue for the three months ended March 31, 2026 was $17.2 million and consisted of royalty revenue from worldwide net sales of MAVYRET®/MAVIRET® (glecaprevir/pibrentasvir), AbbVie’s treatment for hepatitis C virus, compared to $14.9 million for

View on SEC.gov

170 earnings releases filed in the last 30 days. Browse all earnings releases →

ENANTA PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0001193125-26-216735

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.